

References

S-141

1. InterQual® Level of Care Criteria 2019. Acute Care Adult. McKesson Health Solutions, LLC.
2. Canadian Cancer Society. Liver Cancer. 2016.
3. NIH National Cancer Institute. Cryosurgery in cancer treatment: Questions and answers. 2016.
4. Littrup P, Aoun H, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors long-term experience of a large U.S. series. *Abdom Radiol*. 2016;41(4):757-780.
5. American Cancer Society. Tumor Ablation for Liver Cancer. 2016.
6. European Society for Medical Oncology. Microwave Ablation for Treating Liver Metastases. 2016.
7. FDA/CEDR resources page. Food and Drug Administration Web site. 2017.
8. Song K. Percutaneous cryoablation for hepatocellular carcinoma. *Clin Mol Hepatol*. 2016;22:509-515.
9. Kang T, Rhim H, Song K, et al. Radiofrequency ablation of hepatocellular carcinoma with a “Nodule-in-Nodule” appearance: Long-term follow-up and clinical implications. *Cardiovasc Intervent Radiol*. 2017;40:401-409.
10. Changyong E, Wang D, Yu Y, et al. Efficacy comparison of radiofrequency ablation and hepatic resection for hepatocellular carcinoma: A meta-analysis. *J Cancer Res Ther*. 2017;13:625-630.
11. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hepatobiliary cancers. Version 2021.
12. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Neuroendocrine and adrenal tumors. Version 2.2021.
13. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Colon cancer. Version 2.2021.
14. Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. *World J Gastrointest Pharmacol Ther*. 2016;7(4):477.
15. Wang WD, Xu LF, Zhang L, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma with the Milan criteria: A meta-analysis. *Korean J Radiol*. 2018;19(4):613-622.
16. Lurje I, Czigan Z, Bednarsch J, et al. Treatment strategies for hepatocellular carcinoma—A multidisciplinary approach. *Int J Mol Sci*. 2019;20(6):1465.
17. Zhao WJ, Zhu GQ, Wu YM, et al. Comparative effectiveness of radiofrequency ablation, surgical resection and transplantation for early hepatocellular

- carcinoma by cancer risk groups: Results of propensity score-weighted analysis. *Onco Targets Ther.* 2019;12:10389.
18. Kutlu OC, Chan JA, Aloia TA, et al. Comparative effectiveness of first-line radiofrequency ablation versus surgical resection and transplantation for patients with early hepatocellular carcinoma. 2017;123(10):1817-27.
 19. Hof J, Wertenbroek MW, Peeters PM, Widder J, et al. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. *Br J Surg.* 2016;103(8):1055-62.
 20. Ruers T, Van Coevorden F, Punt CJ, Pierie JE, et al. European Organisation for Research and Treatment of Cancer (EORTC); Gastro-Intestinal Tract Cancer Group; Arbeitsgruppe Lebermetastasen und tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG). Local treatment of unresectable colorectal liver metastases: Results of a randomized phase II trial. *J Natl Cancer Inst.* 2017;109(9):djx015.
 21. Meijerink MR, Puijk RS, van Tilborg AAJM, Henningsen KH, et al. Radiofrequency and microwave ablation compared to systemic chemotherapy and to partial hepatectomy in the treatment of colorectal liver metastases: A systematic review and meta-analysis. *Cardiovasc Intervent Radiol.* 2018;41(8):1189-1204.
 22. Lee MW, Raman SS, Asvadi NH, Siripongsakun S, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. *Hepatology.* 2017;65(6):1979-1990.
 23. Giorgio A, Merola MG, Montesarchio L, Merola F, et al. Sorafenib combined with radio-frequency ablation compared with sorafenib alone in treatment of hepatocellular carcinoma invading portal vein: A western randomized controlled trial. *Anticancer Res.* 2016;36(11):6179-6183.
 24. Vietti Violi N, Duran R, Guiu B, Cercueil JP, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: A randomised controlled phase 2 trial. *Lancet Gastroenterol Hepatol.* 2018;3(5):317-325.
 25. Chu HH, Kim JH, Kim PN, Kim SY, et al. Surgical resection versus radiofrequency ablation very early-stage HCC (≤ 2 cm single HCC): A propensity score analysis. *Liver Int.* 2019;39(12):2397-2407.
 26. Zheng L, Zhang CH, Lin JY, Song CL, et al. Comparative effectiveness of radiofrequency ablation vs. surgical resection for patients with solitary hepatocellular carcinoma smaller than 5 cm. *Front Oncol.* 2020;10:399.
 27. Lin Y, Pan XB. Differences in survival between first-line radiofrequency ablation versus surgery for early-stage hepatocellular carcinoma: A population study using the surveillance, epidemiology, and end results database. *Med Sci Monit.* 2020;26:e921782.

28. Lee SH, Jin YJ, Lee JW. Survival benefit of radiofrequency ablation for solitary (3-5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry. *Medicine (Baltimore)*. 2017;96(44):e8486.
29. Zhao WJ, Zhu GQ, Wu YM, Wang WW, et al. Comparative effectiveness of radiofrequency ablation, surgical resection and transplantation for early hepatocellular carcinoma by cancer risk groups: Results of propensity score-weighted analysis. *Onco Targets Ther*. 2019;12:10389-10400.
30. Jia JB, Zhang D, Ludwig JM, Kim HS. Radiofrequency ablation versus resection for hepatocellular carcinoma in patients with Child-Pugh A liver cirrhosis: A meta-analysis. *Clin Radiol*. 2017;72(12):1066-1075.
31. Yu C, Wu S, Zhao J, Lu J, et al. Evaluation of efficacy, safety and treatment-related outcomes of percutaneous radiofrequency ablation versus partial hepatectomy for small primary liver cancer meeting the Milan criteria: A systematic review and meta-analysis of randomized controlled trials. *Clin Res Hepatol Gastroenterol*. 2020;44(5):718-732.
32. Shiina S, Sato K, Tateishi R, Shimizu M, et al. Percutaneous ablation for hepatocellular carcinoma: Comparison of various ablation techniques and surgery. *Can J Gastroenterol Hepatol*. 2018;2018:4756147.
33. National Institute for Health and Care Excellence (NICE). Microwave ablation for treating liver metastases. 2016.
34. Glassberg MB, Ghosh S, Clymer JW, Wright GWJ, et al. Microwave ablation compared with hepatic resection for the treatment of hepatocellular carcinoma and liver metastases: A systematic review and meta-analysis. *World J Surg Oncol*. 2019;17(1):98.
35. Cui R, Yu J, Kuang M, Duan F, et al. Microwave ablation versus other interventions for hepatocellular carcinoma: A systematic review and meta-analysis. *J Cancer Res Ther*. 2020;16(2):379-386.
36. Potretzke TA, Ziemlewicz TJ, Hinshaw JL, Lubner MG, et al. Microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: A comparison of efficacy at a single center. *J Vasc Interv Radiol*. 2016;27(5):631-8.
37. Zhang EL, Yang F, Wu ZB, Yue CS, et al. Therapeutic efficacy of percutaneous microwave coagulation versus liver resection for single hepatocellular carcinoma ≤ 3 cm with Child-Pugh A cirrhosis. *Eur J Surg Oncol*. 2016;42(5):690-7.
38. Li W, Zhou X, Huang Z, Zhang K, et al. Short-term and long-term outcomes of laparoscopic hepatectomy, microwave ablation, and open hepatectomy for small hepatocellular carcinoma: A 5-year experience in a single center. *Hepatol Res*. 2017;47(7):650-657.

39. Philips P, Scoggins CR, Rostas JK, McMasters KM, et al. Safety and advantages of combined resection and microwave ablation in patients with bilobar hepatic malignancies. *Int J Hyperthermia*. 2017;33(1):43-50.
40. Song P, Sheng L, Sun Y, An Y, et al. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. *Oncotarget*. 2017;8(31):51792-51799.
41. Xu Y, Shen Q, Wang N, Wu PP, et al. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. *Chin J Cancer*. 2017;36(1):14.
42. Chen ZB, Qin F, Ye Z, Shen SQ, et al. Microwave-assisted liver resection vs. clamp crushing liver resection in cirrhosis patients with hepatocellular carcinoma. *Int J Hyperthermia*. 2018;34(8):1359-1366.
43. Chong CCN, Lee KF, Chu CM, Chan AWH, et al. Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: Application of ALBI score to patient selection. *HPB (Oxford)*. 2018;20(6):546-554.
44. Chong CCN, Lee KF, Cheung SYS, Chu CCM, et al. Prospective double-blinded randomized controlled trial of Microwave versus RadioFrequency Ablation for hepatocellular carcinoma (McRFA trial). *HPB (Oxford)*. 2020;22(8):1121-1127.